Nalmefene oral - Acorda Therapeutics/Lundbeck A/S

Drug Profile

Nalmefene oral - Acorda Therapeutics/Lundbeck A/S

Alternative Names: CPH-101; JF-1; Lu AA36143; Nalmetrene; NIH-10365; ORF-11676; Selincro; Soberal

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator Rockefeller University; University of Miami
  • Developer Lundbeck A/S; Otsuka Pharmaceutical; Somaxon Pharmaceuticals
  • Class Antidotes; Morphinans; Neuroprotectants; Small molecules; Smoking cessation therapies
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alcoholism
  • Discontinued Gambling; Interstitial cystitis; Pruritus; Rheumatoid arthritis; Shock; Smoking withdrawal

Most Recent Events

  • 31 Mar 2017 Phase-III development for Alcoholism is ongoing in Japan (PO) (Otsuka pipeline, March 2017)
  • 01 Jul 2016 Otsuka Pharmaceutical completes a phase III trial in Alcoholism in Japan (PO) (NCT02364947)
  • 01 Feb 2016 Otsuka Pharmaceutical initiates enrolment in a phase I trial in Healthy volunteers in Japan (NCT02679469)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top